Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule with the chemical formula C22H19N3OS and a molecular weight of approximately 373.47 g/mol[1][7]. It is structurally characterized as a benzodiazepine derivative containing both thiophene and azetidinol moieties. The compound has not been approved for any medical use in the US or elsewhere and does not have any known clinical indications or completed clinical trials[1]. Its mechanism of action, pharmacological activity, and therapeutic potential are not described in publicly available sources. It has been referenced as a ligand (VGA) in structural biology databases but without further pharmacological annotation[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[(3S)-5-phenyl-3-thiophen-2-yl-3H-1,4-benzodiazepin-2-yl]azetidin-3-ol.